JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

SLITRK2 as a prognostic and immunological biomarker in gastric cancer

  • 0Department of Oncology, Huizhou Central People's Hospital, Huizhou, 516000, Guangdong Province, China.
Discover Oncology +

|

November 16, 2024

|

November 16, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

SLITRK2 (SLIT and NTRK-like protein 2) expression is linked to advanced cancer stages and poor survival across many cancers. It also influences immune cell infiltration, suggesting its potential as a prognostic biomarker, especially in gastric cancer.

Area Of Science

  • Oncology
  • Molecular Biology
  • Immunology

Background

  • SLITRK2 (SLIT and NTRK-like protein 2) is a transmembrane protein involved in neurite outgrowth.
  • Previous studies indicated SLITRK2 overexpression in glioma.
  • The expression pattern, prognostic significance, and immunologic role of SLITRK2 in various cancers were largely unknown.

Purpose Of The Study

  • To investigate the expression pattern of SLITRK2 across various cancer types.
  • To analyze the prognostic value of SLITRK2 in pan-cancer survival.
  • To explore the association of SLITRK2 with immune infiltration and tumor characteristics.

Main Methods

  • Utilized TCGA and GTEx databases for pan-cancer SLITRK2 expression analysis.
  • Performed Kaplan-Meier survival analysis for overall survival (OS) and disease-free survival (DFS).
  • Evaluated correlations between SLITRK2 expression, immune cell infiltration, tumor mutation burden (TMB), microsatellite instability (MSI), and gene mutations. Analyzed SLITRK2 expression in gastric cancer (GC) tissues via tissue microarray (TMA).

Main Results

  • SLITRK2 expression varied significantly across different cancer types.
  • Elevated SLITRK2 expression correlated with advanced tumor stage, poor OS, and reduced DFS.
  • SLITRK2 expression was significantly associated with immune cell infiltration and marker expression. In GC, high SLITRK2 expression correlated with differentiation, lymph node metastasis, AJCC stage, TNM stage, and poorer survival outcomes.

Conclusions

  • SLITRK2 may serve as a prognostic biomarker, potentially by regulating immune cell infiltration.
  • High SLITRK2 expression is confirmed to be correlated with a poor prognosis in gastric cancer patients.

Keywords: